Next Article in Journal
Inhibition of Development and Metabolism of Dual-Species Biofilms of Candida albicans and Candida krusei (Pichia kudriavzevii) by Organoselenium Compounds
Next Article in Special Issue
Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols
Previous Article in Journal
Examining the Myth of Prescribed Stimulant Misuse among Individuals with Attention-Deficit/Hyperactivity Disorder: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 8
10.3390/ph17081077
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of the N-Butanol Extract of Pulsatilla Decoction on Neutrophils in a Mouse Model of Ulcerative Colitis

by
Yadong Wang
1,2,
Hui Wu
1,2,
Juan Sun
1,2,
Can Li
1,2,
Ying Fang
1,
Gaoxiang Shi
1,2,
Kelong Ma
1,2,
Daqiang Wu
1,2,
Jing Shao
1,2,
Hang Song
1,2,
Tianming Wang
1,2 and
Changzhong Wang
1,2,3,*
1
Department of Pathogenic Biology and Immunology, College of Integrated Chinese and Western Medicine (College of Life Science), Anhui University of Chinese Medicine, Hefei 230012, China
2
Institute of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230012, China
3
Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei 230012, China
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(8), 1077; https://doi.org/10.3390/ph17081077
Submission received: 22 June 2024 / Revised: 8 August 2024 / Accepted: 9 August 2024 / Published: 16 August 2024
(This article belongs to the Special Issue Medicinal Plants: A Natural Approach to Inflammatory Diseases and Conditions Related to Oxidative Stress)
Browse Figures
Review Reports Versions Notes

Abstract

:
Ulcerative colitis (UC) is a chronic inflammatory disease, the incidence of which is increasing worldwide. However, the etiology and pathogenesis of UC remains unclear. The n-butanol extract of Pulsatilla decoction (BEPD), a traditional Chinese medicine, has been shown to be effective in treating UC. This study aimed to explore the molecular mechanism underlying the effects of BEPD on UC, in particular its effects on neutrophil extracellular trap (NET) formation by neutrophils. High-performance liquid chromatography was used to determine the principal compounds of BEPD. UC was induced in mice using dextran sodium sulfate, and mice were treated with 20, 40, or 80 mg/kg BEPD daily for seven days. Colonic inflammation was determined by assessing the disease activity index, histopathology, colonic mucosal damage index, colonic mucosal permeability, and pro- and anti-inflammatory cytokine levels. The infiltration and activation status of neutrophils in the colon were determined by analyzing the levels of chemokine (C-X-C motif) ligand (CXCL) 1 and CXCL2, reactive oxygen species, Ly6G, and numerous NET proteins. The findings suggest that BEPD improved the disease activity index, histopathology, and colonic mucosal damage index scores of mice with UC, and restored colonic mucosal permeability compared with untreated mice. The expression levels of the pro-inflammatory cytokines interleukin-1β, interleukin-6, and tumor necrosis factor-α in colon tissues were significantly decreased, while the expression levels of anti-inflammatory cytokines in colon tissues were significantly increased, exceeding those of control mice. In addition, BEPD reduced the expression of the neutrophil chemokines CXCL1 and CXCL2 in the colon tissue of mice with UC, reduced neutrophil infiltration, reduced reactive oxygen species levels, and significantly reduced the expression of NET proteins. BEPD also significantly reduced NET formation. The results of this study suggest that BEPD exerts therapeutic effects in a murine model of UC by inhibiting neutrophil infiltration and activation in the colon, as well as by inhibiting the expression of key proteins involved in NET formation and reducing NET formation, thereby alleviating local tissue damage and disease manifestations.

1. Introduction

Ulcerative colitis (UC) is a chronic inflammatory disease affecting the colon [1,2]. It manifests clinically as ulcerative lesions in the colon [3], with mucosal and submucosal edema and continuous infiltration of inflammatory cells [4]. Lesions typically develop in the sigmoid colon and gradually disseminate into the descending, transverse, and ascending colon as the condition progresses. Severe cases can involve the entire colon in a continuous distribution [1,5]. Symptoms include weight loss, changes in bowel habits, recurrent bloody diarrhea, and abdominal pain [6]. Epidemiological data have revealed that UC is prevalent in developed regions, such as Europe and the United States, and that its incidence in China is increasing annually. Although the mortality rate of UC is low, long-term chronic inflammation increases the risk of colorectal cancer, other gastrointestinal diseases, infections, and respiratory diseases [7,8,9]. The etiology and pathogenesis of UC remains unclear, resulting in a lack of treatment options, although newly developed drugs have brought relief to some patients with UC. Studying the pathogenesis of UC may provide a theoretical basis for the development of novel therapeutic strategies.
Damage to the colonic mucosa results in the immediate recruitment and activation of polymorphonuclear neutrophils (PMNs). Activated PMNs secrete reactive oxygen species (ROS) and inflammatory factors, inducing further tissue damage [10], which often presents as acute ulcers. The average lifespan of PMNs following tissue infiltration is 24–48 h. However, production of inflammatory factors such as tumor necrosis factor (TNF)-α, interleukin (IL)-8, and IL-1 in the colon leads to the continuous recruitment and activation of PMNs. This results in the main pathological feature of UC: chronic ulcerative damage to the colonic mucosa. Previous studies have confirmed the uncontrolled accumulation and persistence of PMNs in damaged mucosal lamina propria [11]. A vicious cycle is formed, in which infiltrating PMNs damage the mucosa, which in turn leads to further PMN infiltration. This is the foundation of the development of clinicopathological changes in patients with UC. Therefore, some scholars regard the degree of neutrophil infiltration in the lamina propria of the intestinal mucosa, the degree of accumulation in the crypt, the destruction of the crypt, and the formation of crypt abscesses as morphological markers and severity indicators of active UC [12,13,14,15].
PMNs constitute the first line of immune defense, with their primary role involving phagocytosis of pathogenic microorganisms. Inside PMNs, phagosomes are fused with intracellular lysosomes to form phagocytic lysosomes, which kill and degrade encapsulated pathogens using lysosomal enzymes. This method does not result in tissue damage; however, it is limited by the number of PMNs available. PMNs can also kill pathogenic microorganisms by releasing antimicrobial factors, including granular enzymes, ROS, and neutrophil elastase (ELANE). Cui et al. [16] showed that PMNs release a large amount of granular proteins and ELANE into the extracellular space, inducing tumor cell apoptosis. ELANE exists only in neutrophils and can hydrolyze fibronectin, proteoglycans, type IV collagen, and extracellular matrix proteins, causing tissue damage, prolonging the inflammatory response time, and preventing wound healing. However, the various enzymes released are rapidly diluted by the large amount of exudate in the inflamed area, decreasing their effectiveness, and they subsequently undergo rapid and complete neutralization by anti-proteases. Neither phagocytosis nor the secretion of antimicrobial factors can explain the relationship between infiltrating PMNs and inflammation. However, another PMN mechanism of action has been identified. PMNs release neutrophil extracellular traps (NETs), a DNA network fiber structure that combines various proteins such as histones, ELANE, and myeloperoxidase (MPO), maintaining them at high concentrations at the inflammatory site to resist neutralization. The DNA network fiber structure also entraps pathogenic microorganisms, exerting a powerful killing effect but also causing severe tissue damage, playing a key role in the development of UC [17,18,19,20].
Traditional Chinese medicine believes that the etiology and pathogenesis of ulcerative colitis is the weakness of spleen and stomach, which leads to damp-heat obstructing the intestinal tract, blocking qi machinery, and damaging the intestinal collaterals [21]. Pulsatilla decoction (PD) is a Traditional Chinese medicine formulation recorded in Shang Han Lun, a classic work of Chinese medicine written by Zhang Zhongjing in the Eastern Han Dynasty. Each dose of Pulsatilla decoction consists of Pulsatilla Chinensis (Bunge) Regel 15 g, Phellodendron chinense C.K. Schneid 12 g, Coptis chinensis Franch 6 g, Fraxinus rhynchophylla Hance 12 g, and is boiled with water to obtain the decoction. It holds the function of clearing away heat, detoxifying cooling blood, drying dampness, and stopping dysentery [22]. PD is widely used in the treatment of UC [23,24]. Modern pharmacological studies have found that the main active ingredients of PD include anemoside B4, berberine, phellodendrine, jatrorrhizine, epiberberine, palmatine, magnoflorine, berberrubine, esculin, esculetin, fraxin and fraxetin, etc., and functioning anti-inflammatory, anti-viral, anti-oxidation, anti-tumor, anti-ulcer, antibiotics and antifungal activity. We have previously demonstrated that BEPD exerts a therapeutic effect on UC by inhibiting PMN infiltration and the release of pro-inflammatory cytokines [25,26]. In this study, the impact of BEPD on PMNs and NETs were investigated, to determine whether this mechanism underlies the therapeutic effect of BEPD on UC.

2. Results

2.1. Main Components of BEPD

To identify the main active compounds in BEPD, high-performance liquid chromatography (HPLC) was used to examined BEPD (Figure 1). Anemoside B4, phellodendrine, esculin, esculetin, epiberberine, berberine, and jatrorrhizine were selected for identification based on their respective BEPD criteria. The retention times, peak areas, and contents are listed in Table 1. Among these constituents, anemoside B4, berberine, and esuclin were the most abundant.

2.2. BEPD Significantly Improves the General Condition and Disease Activity Index (DAI) Scores of Mice with UC

The UC mouse model was successfully established. Compared with control mice, model group mice began to lose weight on day 4 (Figure 2A), developing loose and then bloody stools. These changes occurred alongside increased DAI scores (p < 0.05) (Figure 2B). From day 9, the trend of weight loss slowed, consistent with the self-healing characteristics of DSS-induced UC [27], but weight loss continued until the end of the experiment. The weight of all treated mice began to increase and the DAI score began to decrease from the second day of treatment. By the third day of treatment, there was a significant difference between the treatment and model groups (p < 0.05). At the end of the experiment, the DAI score in the high-dose BEPD (BEPD-H) group was significantly lower than that in the medium-dose BEPD (BEPD-M), low-dose BEPD (BEPD-L), and mesalazine (Mes) groups, indicating superior treatment efficacy (p < 0.05). The effect in the Mes group was greater than that in the BEPD-M and BEPD-L groups.

2.3. Impact of BEPD on UC Lesions

UC is accompanied by the formation of chronic ulcers in the colonic mucosa, as well as changes in colon length and histopathological and colonic mucosa damage index (CMDI) scores. Compared with control mice, model mice had significantly shorter colons (p < 0.01). After one week of treatment, the colon length of the Mes and BEPD-L groups did not differ significantly compared with the model group, whereas the BEPD-H and BEPD-M groups showed a significant recovery in colon length (p < 0.05), with the greatest effect in the BEPD-H group (Figure 3A,B).
HE staining of colon tissue revealed that compared to control group mice, model group mice exhibited obvious signs of colonic mucosal edema, erosion, ulceration, mucosal layer damage, and inflammatory cell infiltration (Figure 3C), with higher histopathological (Figure 3D) and CMDI scores (p < 0.01) (Figure 3E). Colonic mucosal edema, erosion, ulceration, mucosal layer damage, and inflammatory cell infiltration were reduced in all treated mice compared with model mice, and histopathological and CMDI scores decreased. However, there were no significant differences between the Mes and model groups, whereas there were significant differences between all BEPD treatment groups and the model group.
Colonic mucosal permeability was significantly increased in model group mice, consistent with the mucosal damage observed with hematoxylin-eosin (HE) staining (Figure 3F). Mice treated with Mes (p < 0.05) or BEPD (p < 0.01) showed a decrease in colonic mucosal permeability, with the effect of BEPD significantly greater than that of Mes (p < 0.05). BEPD exhibited a dose-dependent effect, with BEPD-H having the greatest impact.

2.4. Effects of BEPD on Cytokine Production

ELISA results showed that the levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were significantly increased in the colon tissues and serum of model mice, whereas the levels of anti-inflammatory cytokines (IL-4 and IL-10) were decreased, consistent with the disease manifestations of UC. In mice treated with Mes, IL-1β levels in the colon tissues and serum (p < 0.01), IL-6 levels in the serum, and TNF-α levels in colon tissues decreased (p < 0.05), while IL-10 levels decreased (p < 0.05) and IL-4 levels increased (p < 0.05). This suggests that Mes mainly exerts its therapeutic effect on UC through effects on IL-1β and IL-4. BEPD-H group mice showed a significant decreases in the levels of IL-1β, IL-6, and TNF-α in the colon tissues (p < 0.05), which returned to the levels seen in control mice. Serum TNF-α levels did not differ significantly between BEPD and model group mice. However, anti-inflammatory cytokine levels in colon tissues increased significantly in BEPD group mice, exceeding the levels seen in control mice (p < 0.05) (Figure 4). This indicates that BEPD plays a therapeutic role in UC by inhibiting the release of pro-inflammatory cytokines and promoting the release of anti-inflammatory cytokines in colon tissues to alleviate the inflammatory response.

2.5. Effects of BEPD on Chemokine Production and PMN Infiltration and Activation

Since PMNs play an important role in the development of UC, it has been speculated that BEPD has therapeutic effects on PMNs in UC. Levels of the PMN chemokines (C-X-C motif) ligand (CXCL)1 and CXCL2 were decreased in colon tissues of all treated mice compared with model mice, especially those treated with high- and medium-dose BEPD (p < 0.01) (Figure 5A).
Immunofluorescence staining of Ly6G, a PMN-specific marker, revealed large numbers of infiltrating PMNs in the colonic mucosa of model mice (p < 0.01), which were reduced to varying degrees by treatment (p < 0.01) (Figure 5B,C). BEPD treatment showed a certain dose-dependent manner; BEPD-H was more effective at reducing PMN infiltration than Mes (p < 0.05).
PMN activation was evaluated by staining for ROS. ROS cytoplasmic staining significantly increased in the colon tissues of model mice (p < 0.01), and decreased in all treated mice (p < 0.05), with BEPD-H treatment showing the most significant effect (p < 0.01), and BEPD-M and BEPD-L treatment showing similar effects to Mes (Figure 5D,E). These results indicate that the effects of BEPD on UC are related to the infiltration and activation of PMNs.

2.6. Effects of BEPD on the Formation and Release of NETs

Western blotting (WB) showed that compared with control mice, the expression levels of key proteins involved in NET formation (PAD4, ELANE, MPO, and Cit H3) were significantly increased in the colonic mucosa of model mice (p < 0.01). Treatment partially reversed these changes. In Mes group mice, the expression levels of PAD4, MPO, and Cit H3 decreased to varying degrees compared with those in model mice (p < 0.05), but remained significantly higher than those in control mice (p < 0.01). Mes showed no effect on the levels of ELANE. This indicates that although Mes can reduce the transcriptional and translational activities of ELANE, MPO, and PAD4 in model mice, chromatin decondensation is still active. Mice treated with high-dose BEPD showed a significant decrease in the expression levels of ELANE (p < 0.05), PAD4 (p < 0.01), MPO (p < 0.01), and Cit H3 (p < 0.01) compared with model and Mes group mice. ELANE and Cit H3 expression levels in the low-dose group were similar to those in the Mes treatment group, and in the medium-dose group were intermediate between those in the high- and low-dose groups; the expression levels of PAD4 and MPO did not differ from those in model mice (Figure 6).
Immunohistochemistry showed that staining of these key proteins increased significantly in model mice, as did staining of the NET-associated components MMP-8 and -9 (p < 0.01). MMP-8 and -9 were expressed in the cytoplasm, while the key proteins involved in NET formation, such as PAD4, ELANE, and MPO were expressed in both the cytoplasm and the nucleus (Figure 7A–E), indicating the involvement of these proteins in NET formation. Compared with model mice, staining of MMP-8, MMP-9, PAD4, ELANE, and MPO decreased following BEPD-H treatment (p < 0.01). The high-dose group showed the most significant effect, indicating a dose-dependent response.
After NET formation, these proteins are released into the extracellular space and enter the intestinal cavity as a result of mucosal damage, eventually being excreted from the body in the feces. Therefore, fecal samples were analyzed by using ELISA to detect NET-related proteins. Compared with control mice, the protein expression levels of MPO, ELANE, and MMP-8 and -9 increased significantly in the feces of model mice (p < 0.05) (Figure 7F). The protein expression levels of ELANE and MPO decreased in Mes group mice compared with model mice (p < 0.05), while the expression level of MMP-9 increased slightly (p < 0.05). There was no difference in MMP-8 expression levels. This suggests that treatment of UC with Mes does not greatly impact NET formation. BEPD group mice showed significantly decreased protein expression levels of MPO (p < 0.05), ELANE (p < 0.01), and MMP-8 (p < 0.05) and -9 (p < 0.01), compared with those in model and Mes group mice, with the high-dose group exhibiting the greatest effects. This indicates that BEPD may alleviate UC through effects on NET formation.
The transcription and translation of ELANE, MPO, and PAD4, the key proteins of NET formation, are enhanced. PAD4 is activated and incorporated into the nucleus, in response to ROS, which degrades nucleosome histones and uncoils chromatin. Therefore, this study speculated that there may be a correlation between the expression of ROS and Cit H3 during NET formation. A Pearson correlation analysis between the WB analysis data of Cit H3 and the immunohistochemical quantitative data of ROS showed a strong correlation between ROS and Cit H3 (rs = 0.989, p < 0.001).

2.7. Effect of BEPD on Extracellular NET

Immunofluorescence co-localization analysis was used to demonstrate the formation of extracellular NET. By comparing Pearson’s and overlap, differences in NET formation in the colon tissues of mice were observed. MPO and Cit H3 co-located with DNA is a NET marker (Figure 8A); significantly increased NET formation was observed in the colon tissues of model mice compared with control mice (p < 0.01). Compared with model mice, Mes group mice showed a decrease in NET formation (p < 0.05), which was still significantly greater than that in control mice (p < 0.01), consistent with the decrease in PMN infiltration after treatment; BEPD group mice showed a dose-dependent decrease in NET formation (p < 0.01) (Figure 8B). As ELANE and MPO co-located with DNA (Figure 8C), significantly increased NET formation was observed in the colon tissues of model mice compared with control mice (p < 0.01). Compared with model mice, Mes group mice showed a decrease in NET formation (p < 0.01), which was still significantly greater than that in control mice (p < 0.01); BEPD group mice showed a dose-dependent decrease in NET formation (p < 0.01) (Figure 8D). Combined with the changes in PMN infiltration in the colonic mucosal tissue, this indicates that BEPD can inhibit extracellular NET formation.

3. Discussion

UC is a chronic intestinal inflammation characterized by colonic damage. Once it develops, it becomes a lifelong disease. The clinical incidence of UC is increasing [6], leading to a rapid increase in the number of patients. Consequently, the demand for UC treatment is escalating, resulting in the introduction of new drugs to help some patients maintain disease remission under drug control. However, long-term drug treatment for chronic diseases can lead to numerous adverse reactions. Aminosalicylic acid drugs [28] are the primary treatment for UC. Although the efficacy and safety of current clinical treatment drugs have improved, some patients remain insensitive to them [29,30], while others may experience severe adverse reactions [31]. Glucocorticoids (GCS) are also commonly used in UC treatment, but studies have shown that their use can disrupt the intestinal flora, increase the risk of intestinal flora imbalance, and cause drug resistance. Due to their significant side effects, they can only be used for short periods [32]. Immunosuppression has rapidly developed over the past 20 years, but it has been observed in clinical practice that many patients are not resistant to the drugs, leading to drug withdrawal due to adverse reactions [33]. Biological preparations have emerged as a new treatment for UC in recent years, but their high cost limits their widespread use [34].
In the present study, BEPD was used to investigate its possible mechanism of action. The mechanism of action of anti-UC drugs has been widely described in the existing literature, and studies have shown that their pharmacological mechanisms may involve maintaining the homeostasis and diversity of intestinal flora, increasing short chain fatty acid content and repairing the colonic mucosal barrier [35], but the mechanism of BEPD against UC is still unclear. At present, there is no literature report on the effect of BEPD on PMNs, and the formation and release of NETs in colon tissue. Therefore, this study will elaborate the effects of BEPD on the regulation of PMNs in colon tissue, the repair of colon tissue, and the formation and release of NETs, in order to reveal the pharmacological mechanism of BEPD.
The present study investigated the efficacy and underlying mechanisms of BEPD in treating mice with UC, and the findings demonstrated that BEPD exerts a protective effect on the colonic mucosa of UC mice by inhibiting the recruitment and chemotaxis of PMNs in the intestinal lamina propria. Mucosal epithelial injury, crypt abscess formation [18,36], diarrhea, hematochezia, weight loss [37], and other manifestations are typical pathological changes observed in UC mice. This study demonstrates that BEPD can effectively improve these symptoms by promoting restoration of the colonic mucosa. PMNs play a crucial role in the development and incidence of UC [38] as they are key inflammatory cells involved in the body’s defense reaction [18]. During UC progression, there is abnormal infiltration and accumulation of PMNs [19,20,39] in the lamina propria of intestinal mucosa along with increased activity levels [14]. The results indicate that BEPD effectively reduces DAI score by modulating PMN activity. Histological examination using HE staining revealed significant pathological changes in colonic mucosa from model group mice including edema, erosion, ulceration, disruption of the mucosal layer, and infiltration of inflammatory cells compared to normal group mice. However, treatment with medium- and high-dose BEPD restored the integrity of the mucosal layer while significantly reducing inflammatory infiltration compared to the low-dose BEPD group or the Mes group. These results indirectly indicated that BEPD improves overall condition, DAI score, and mitigates the inflammatory response in UC mice.
UC is primarily characterized by chronic inflammation in the intestines. During the disease progression, a substantial release of pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6) occurs in the colon tissue, while there is a reduction in the secretion of anti-inflammatory factors (such as IL-4 and IL-10). Additionally, numerous inflammatory cells actively participate in local inflammatory responses. Among these cells, IL-1 β is produced and secreted by various cell types and typically plays a crucial role in host defense mechanisms. It is associated with pain perception, inflammation regulation, and autoimmunity processes [40]. Furthermore, IL-1 β also contributes to neuroprotection as well as tissue remodeling and repair mechanisms [41]. On the other hand, IL-4 can effectively mitigate pathological inflammation by promoting wound healing and fibrosis reduction [42]. Neutrophils serve as the body’s first line of cellular defense against pathogens and are among the initial cells recruited to sites of inflammation [43]. Subsequently activated locally recruited PMN play defensive roles such as phagocytosis, immunity and cause tissue damage. Activated PMNs continuously release ROS, ELANE, MMP, and MPO [39,44] in the intestinal mucosa, significantly enhancing tissue damage while losing their protective effect and contributing to tissue injury scenarios. This study demonstrated a significant increase in pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, inhibition of anti-inflammatory cytokines IL-4 and IL-10, as well as a significant increase in chemokines CXCL1 and CXCL2 in the colon tissues of mice with UC. The If and IHC results showed increased expression of Ly6G and ROS in the colon tissues of UC mice, indicating massive recruitment and activation of PMNs. Additionally, histopathological score, CMDI score, and mucosal permeability were significantly increased in mice with UC-induced intestinal mucosal tissue damage. After treatment with BEPD, levels of pro-inflammatory cytokines decreased significantly while anti-inflammatory cytokines increased significantly in the colon tissues of mice. This further confirmed the anti-inflammatory function of BEPD. The expression levels of chemokines CXCL1 and CXCL2 decreased significantly along with reduced expression levels of Ly6G and ROS compared to the model group. These findings indicate that BEPD effectively limits infiltration and activation of neutrophils within colon tissues. Notably, high-dose BEPD exhibited more pronounced effects than the Mes group. The levels of IL-1β were decreased, while those of IL-4 were increased in all treatment groups. Notably, the BEPD treatment group exhibited a superior effect compared to the Mes group, suggesting that BEPD promotes colonic mucosal repair more effectively. These findings were consistent with alterations observed in histopathological score, CMDI score, and mucosal permeability in mice. The findings suggest that BEPD exerts a protective role by suppressing neutrophil chemotaxis and activation, facilitating tissue repair, thereby enhancing the efficacy of UC treatment.
To gain further insights into the effects of BEPD on NET formation and release, this study employed WB, IHC, and fecal samples ELISA to detect the expression of proteins related to NET formation. The results demonstrated increased expression of MPO, PAD4, ELANE, Cit H3, MMP-8, and MMP-9 in UC mice colon tissue indicating enhanced PMN respiratory burst, DNA unwinding, nucleosome degradation, and neutrophil granule protein release leading to extensive NET formation and release. However, after BEPD treatment, there was a decrease in the expression of these proteins with significant efficacy observed in the high-dose group compared to the Mes group. These findings suggest that BEPD can effectively inhibit NET formation and release while protecting colon tissue. Furthermore, immunofluorescence colocalization was utilized to confirm extracellular NET formation in this study which revealed substantial net release in UC mice colon tissue. Following BEPD treatment, there was a dose-dependent reduction in NET formation and release particularly evident in the high-dose group surpassing the effect seen with the Mes group. These results indicate that BEPD can effectively inhibit the formation and release of NET in colonic tissue of UC mice and reduce tissue damage.

4. Materials and Methods

4.1. Experimental Animals

A total of 72 healthy specific pathogen-free female Kunming mice (aged 6–8 weeks, weighing 18–20 g) were purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd. (Taizhou, China; license number SCXK [Su] 2020–0009). The mice were housed in a disease-free environment, with a humidity of 50–55%, a temperature of 22 ± 2 °C, a 12 h light/dark cycle, and free access to food and water. The animal experiments were approved by the Experimental Animal Ethics Committee of Anhui University of Traditional Chinese Medicine (permit number 2023007) and were conducted in accordance with Chinese legislation on the ethical use and care of laboratory animals.

4.2. Qualitative Analysis of BEPD Extract via HPLC

BEPD was prepared as previously described [44]. Radix pulsatillae, Cortex phellodendri, Rhizoma coptidis and Cortex fraxini were mixed at a ratio of 15:12:6:12, soaked in 80% ethanol, and heated in a 70 °C water bath overnight to extract the Pulsatilla decoction, refluxed evaporation for 3 h and filter after cooling. The process was repeated three times. The filtrate was combined, and then extracted with petroleum ether, ethyl acetate, and n-butanol to extract different effective parts separately. The extract was dried and evaporated at 80 °C by rotary evaporator, and finally, the BEPD was obtained. To identify the main active compounds in BEPD, we selected esuclin, aescin, epiberberine, berberine, phellodendrine, japonin, and anisidin B4 for analysis. High-performance liquid chromatography (HPLC) was performed to determine the main active compounds in BEPD. A sample of BEPD powder weighing 0.2 g was precisely weighed and passed through No. 2 sieve (850 μm ± 29 μm 24 mesh) and placed in a conical flask with stopper, and a mixed solution of methanol-hydrochloric acid (100:1) totaling 50 mL was accurately added. The bottle was sealed, weighed, and subjected to ultrasonic treatment (Power: 250 W, Frequency: 40 kHz) for 30 min. The bottle was then cooled, reweighed, and brought up to the original weight using methanol. The resulting mixture was shaken well, filtered, and 2 mL of the filtrate was precisely measured and placed in a 10 mL volumetric flask. Methanol was added into the volumetric flask for constant volume, shaken well, filtered, filtrate was taken. Liquid chromatography conditions: Syncronic C18, Dim 250 mm × 4.6 mm, 5 μm chromatographic column was used. Octadecyl silane bonded silica as filler, with acetonitrile (0.05 mol/L):potassium dihydrogen phosphate solution (50:50) (Added 0.4 g sodium dodecyl sulfate to each 100 mL mobile phase, and adjusted the pH value to 4.0 with phosphoric acid) as mobile phase, and the flow rate was 1 mL/min. The evaluation was conducted using an external standard quantitative method.

4.3. Establishment and Treatment of the UC Model

The 72 female Kunming mice were randomly divided into six groups, using the method developed by Ma et al. [38,39]. UC was induced in all mice except those in the control group by replacing drinking water with 3.0% dextran sodium sulfate (DSS) aqueous solution for seven days. Mice in the control group drank distilled water for seven days. After UC induction, the 60 mice with UC were divided into five groups according to body weight: model, Mes, BEP-H, BEPD-M, and BEPD-L. Mice in the control and model groups were administered with 0.5 mL·kg−1 normal saline, mice in the Mes group were administered with 200 mg·kg−1 Mes [45], and mice in the BEPD-H, BEPD-M, and BEPD-L groups were administered with 80, 40, and 20 mg·kg−1 BEPD, respectively. Mes and BEPD were prepared with normal saline; all solutions were administered by gavage once daily for seven days.

4.4. General Condition of Mice and Disease Activity Index Scores

The general health of mice, including their mental state, diet, activity, and fur condition, was monitored every day. Daily food intake, body mass, bowel movements, fecal blood, and mortality were recorded for each group. The DAI [46] score was calculated based on the criteria listed in Table 2.

4.5. Colonic Mucosal Permeability Detection

After a 12-h fast, 200 mL fluorescein isothiocyanate-dextran (FITC-dextran; 500 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) was administered to each mouse by oral gavage. Mice were euthanized 4 h later and venous blood was collected. Serum was obtained through centrifugation and its absorbance was measured using a fluorescence spectrophotometer (excitation wavelength, 490 nm; emission wavelength, 520 nm). The serum concentration of FITC-dextran was calculated using a standard curve.

4.6. Histopathology

After mice were euthanized and blood was collected, a segment of colon approximately 0.5 cm long was cut 1 cm from the anus and immediately immersed in a 4% paraformaldehyde solution for 48 h to fix the tissue. The tissue was then dehydrated, embedded in paraffin, sectioned, and stained with HE staining to facilitate microscopic observation of the pathological changes in the mouse colon [47]. The colonic mucosa damage index (CMDI) score was calculated [48] and images were captured. Table 3 and Table 4 list these criteria.

4.7. Enzyme-Linked Immunosorbent Assay

The expression levels of IL-1β, IL-6, TNF-α, IL-4, IL-10, chemokine CXCL1, and CXCL2 in serum and colon tissue samples were detected using enzyme-linked immunosorbent assay (ELISA) kits (Shanghai Jianglai Industrial Co., Ltd., Shanghai, China). Absorbance was measured at a wavelength of 450 nm using a microplate reader and a standard curve was used for concentration conversion. The expression levels of MPO, ELANE, matrix metalloproteinase (MMP)-8, and MMP-9 in feces were also detected using ELISA kits (Shanghai Jianglai Industrial Co., Ltd., Shanghai, China).

4.8. Immunohistochemistry

Paraffin-embedded colon tissue samples were sectioned, dewaxed, rehydrated with gradient ethanol, and treated with sodium citrate buffer (10 mM, pH 6.0) for 20 min, followed by 3% hydrogen peroxide for 10 min to inactivate endogenous peroxidase. The sections were incubated with polyclonal antibodies recognizing MMP-8 (1:200; catalog number M09JA12; Chengdu Zhengneng Biotechnology Co., Ltd., Chengdu, China), MMP-9 (1:200; catalog number L05DE16; Chengdu Zhengneng Biotechnology Co., Ltd.), MPO (1:200; catalog number M05JA20; Chengdu Zhengneng Biotechnology Co., Ltd.), protein arginine deiminase (PAD)4 (1:5000; catalog number 00102732; Proteintech Group, Rosemont, IL, USA), ELANE (1:200; catalog number M05JA20; Chengdu Zhengneng Biotechnology Co., Ltd.), and ROS (1:200; catalog number 53q9220; Affinity Biosciences, Cincinnati, OH, USA) at 4 °C overnight. They were then incubated with the secondary antibody for 20 min, following which the color was developed with 3,3-diaminobenzidine. Sections were counterstained with hematoxylin, sealed with neutral resin, and observed under a light microscope (Olympus BX51; Fulai Optical Technology Co. Ltd., Shanghai, China). Image analysis was performed using Image J 1.53k software.

4.9. Immunofluorescence

Paraffin-embedded colon tissue samples were sectioned, dewaxed, rehydrated with gradient ethanol, and treated with sodium citrate buffer (10 mM, pH 6.0) for 20 min, followed by 3% hydrogen peroxide for 10 min to inactivate endogenous peroxidase. The sections were incubated with a rabbit anti-mouse Ly6G polyclonal antibody (1:500; catalog number M09JA12; Chengdu Zhengneng Biotechnology Co., Ltd.) overnight at 4 °C followed by a goat anti-rabbit IgG (Alexa Fluor 488) fluorescent secondary antibody (1:500; catalog number L08AU3A; Chengdu Zhengneng Biotechnology Co., Ltd.) for 20 min. The nucleus was stained with DAPI (Shandong Sijie Biotechnology Co., Ltd., Jinan, China) for 5 min, and sections were observed under a fluorescence microscope within 1 h.

4.10. Western Blotting

Protein was extracted from colon tissue using phenylmethylsulfonyl fluoride (catalog number 23184510; Biosharp, Hefei, China). Protein separation was performed using sodium dodecyl-sulfate polyacrylamide gel electrophoresis and proteins were transferred onto a polyvinylidene fluoride membrane using electroblotting. The membrane was blocked with 5% non-fat milk powder for 2 h and then the membranes were incubated with rabbit anti-mouse PAD4 (1:1000), rabbit anti-mouse citrullinated histone H3 (Cit H3; 1:1000; catalog number 00057440; Proteintech Group), rabbit anti-mouse MPO (1:5000), and rabbit anti-mouse β-actin (1:10,000; catalog number 380624; Chengdu Zhengneng Biotechnology Co., Ltd.) antibodies overnight at 4 °C. Subsequently, the membrane was incubated with secondary antibodies for 1 h and proteins were detected with enhanced chemiluminescence.

4.11. NET Visualization

Extracellular NETs were detected using immunofluorescence co-localization. Paraffin-embedded colon tissue samples were sectioned, dewaxed, rehydrated with gradient ethanol, and treated with sodium citrate buffer (10 mM, pH 6.0) for 20 min, followed by 3% hydrogen peroxide for 15 min in the dark to inactivate endogenous peroxidase. Then, sections were incubated with 3% BSA-PBS solution for 30 min at room temperature, followed by rabbit anti-mouse ELANE (1:200) and rabbit anti-mouse MPO (1:100) polyclonal antibodies overnight at 4 °C. A goat anti-mouse/rabbit HRP polymer from the goat anti-mouse/rabbit multiplex IHC detection kit (double) (Zen-Bio Inc., Durham, NC, USA) was then added to sections, which were incubated at room temperature for 1 h in the dark. After washing with PBS (pH 7.4), TSA-520 was added and sections were incubated at room temperature for 15 min. Antigen retrieval was repeated, and sections were then incubated with rabbit anti-mouse MPO (1:100) and rabbit anti-mouse Cit H3 (1:100) polyclonal antibodies overnight at 4 °C. A goat anti-mouse/rabbit HRP polymer was added and incubated at room temperature for 1 h in the dark. TSA-570 was added and sections were incubated at room temperature for 15 min. Sections were counterstained with DAPI, incubated in the dark at room temperature for 5 min, mounted, and observed under a fluorescence microscope within 1 h.

4.12. Statistical Analysis

All data were analyzed using SPSS software version 23.0 (IBM Corp., Armonk, NY, USA). Measurement data are expressed as mean ± standard deviation, and differences between groups were compared using one-way analysis of variance, with p < 0. 05 considered to indicate a statistically significant difference. The experiments were repeated three times.

5. Conclusions

The release of NETs by PMNs may be a major factor in the pathogenesis of UC. NETs are formed through a variety of factors and respond to a variety of stimuli, which makes it difficult for the single-component drugs currently used in clinical practice to play an effective role in the treatment of UC by regulating the release of NETs from PMNs. The findings suggest that BEPD regulates NET formation in PMNs through multiple targets and pathways to play a therapeutic role in UC.

Author Contributions

Y.W.: investigation, writing—original draft and review and editing; J.S. (Juan Sun), H.W., and C.L.: investigation, visualization, and validation; C.W.: conceptualization, project administration, methodology, funding acquisition, and writing—original draft and review and editing; G.S. and Y.F.: software and validation; K.M. and D.W.: data analysis and supervision; J.S. (Jing Shao): validation and supervision; T.W.: resources; H.S.: conceptualization and project administration. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Science Foundation of China (grant numbers 82374173, 81774034, 81573725); the Anhui Provincial Key Research and Development Plan (grant number 202104a07020020); and Key Scientific Research Projects of Anhui Provincial Department of Education (grant number KJ2021A0590, 2022AH050500).

Institutional Review Board Statement

All animal procedures related to this experiment were approved by the Animal Ethics Committee of the Institute of Anhui University of Chinese Medicine (Animal Ethics Certificate Number: 2023007) and followed the guidelines of the Chinese legislation on the ethical use and care of laboratory animals.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

BEPD, n-butanol extract of Pulsatilla decoction; BEPD-H, high-dose n-butanol extract of Pulsatilla decoction; BEPD-L, low-dose n-butanol extract of Pulsatilla decoction; BEPD-M, medium-dose n-butanol extract of Pulsatilla decoction; Cit H3, citrullinated histone H3; CMDI, colonic mucosal damage index; CXCL, CXC motif chemokine ligand; DAI, disease activity index; DSS, dextran sulfate sodium; ELANE, neutrophil elastase; ELISA, enzyme-linked immunosorbent assay; FITC-dextran, fluorescein isothiocyanate-dextran; HE, hematoxylin and eosin; HRP, horseradish peroxidase; IL, interleukin; KM, Kunming; Mes, mesalazine; MMP, matrix metalloproteinase; MPO, myeloperoxidase; NET, neutrophil extracellular trap; PAD, protein arginine deiminase; PMN, polymorphonuclear neutrophil; ROS, reactive oxygen species; TNF, tumor necrosis factor; UC, ulcerative colitis.

References

  1. Patnaude, L.; Mayo, M.; Mario, R.; Wu, X.M.; Knight, H.; Creamer, K.; Wilson, S.; Pivorunas, V.; Karman, J.; Phillips, L.; et al. Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair. Life Sci. 2021, 271, 119195. [Google Scholar] [CrossRef]
  2. Xu, N.; Bai, X.L.; Cao, X.L.; Yue, W.J.; Jiang, W.W.; Yu, Z.H. Changes in intestinal microbiota and correlation with TLRs in ulcerative colitis in the coastal area of northern China. Microb. Pathog. 2021, 150, 104707. [Google Scholar] [CrossRef]
  3. Ye, B.; Lai, L.Q. Yu Shi An Chang Fang Ameliorates TNBS-Induced Colitis in Mice by Reducing Inflammatory Response and Protecting the Intestinal Mucosal Barrier. Evid.-Based Complement. Altern. Med. 2021, 2021, 8870901. [Google Scholar] [CrossRef]
  4. Formiga, R.d.O.; Alves Júnior, E.B.; Vasconcelos, R.C.; Guerra, G.C.B.; Antunes de Araújo, A.; Carvalho, T.G.d.; Garcia, V.B.; de Araújo Junior, R.F.; Gadelha, F.A.A.F.; Vieira, G.C.; et al. p-Cymene and Rosmarinic Acid Ameliorate TNBS-Induced Intestinal Inflammation Upkeeping ZO-1 and MUC-2: Role of Antioxidant System and Immunomodulation. Int. J. Mol. Sci. 2020, 21, 5870. [Google Scholar] [CrossRef]
  5. Pavel, F.M.; Vesa, C.M.; Gheorghe, G.; Diaconu, C.C.; Stoicescu, M.; Munteanu, M.A.; Babes, E.E.; Tit, D.M.; Toma, M.M.; Bungau, S. Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. Diagnostics 2021, 11, 1090. [Google Scholar] [CrossRef]
  6. Nyström, E.E.L.; Martinez-Abad, B.; Arike, L.; Birchenough, G.M.H.; Nonnecke, E.B.; Castillo, P.A.; Svensson, F.; Bevins, C.L.; Hansson, G.C.; Johansson, M.E.V. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. Science 2021, 372, 257–286. [Google Scholar] [CrossRef] [PubMed]
  7. Lee, H.S.; Choe, J.; Kim, S.O.; Lee, S.H.; Lee, H.J.; Seo, H.; Kim, G.U.; Seo, M.; Song, E.M.; Hwang, S.W.; et al. Overall and cause-specific mortality in Korean patients with inflammatory bowel disease: A hospital-based cohort study. J. Gastroen Hepatol. 2017, 32, 782–788. [Google Scholar] [CrossRef]
  8. Kassam, Z.; Belga, S.; Roifman, I.; Hirota, S.; Jijon, H.; Kaplan, G.G.; Ghosh, S.; Beck, P.L. Inflammatory Bowel Disease Cause-specific Mortality: A Primer for Clinicians. Inflamm. Bowel Dis. 2014, 20, 2483–2492. [Google Scholar] [CrossRef] [PubMed]
  9. Witte, J.; Shivananda, S.; Lennard-Jones, J.E.; Beltrami, M.; Politi, P.; Bonanomi, A.; Tsianos, E.V.; Mouzas, I.; Schulz, T.B.; Monteiro, E.; et al. Disease outcome in inflammatory bowel disease: Mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand. J. Gastroenterol. 2000, 35, 1272–1277. [Google Scholar] [CrossRef]
  10. Lavie, L.; Dyugovskaya, L.; Polyakov, A.; Rogovoy, O.; Leder, E. Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro. Jove J. Vis. Exp. 2017, 119, e54826. [Google Scholar] [CrossRef]
  11. Ren, J.; Yan, D.; Wang, Y.; Zhang, J.; Li, M.; Xiong, W.; Jing, X.; Li, P.; Zhao, W.; Xiong, X.; et al. Inhibitor of Differentiation-2 Protein Ameliorates DSS-Induced Ulcerative Colitis by Inhibiting NF-κB Activation in Neutrophils. Front. Immunol. 2021, 12, 760999. [Google Scholar] [CrossRef] [PubMed]
  12. Angelidou, I.; Chrysanthopoulou, A.; Mitsios, A.; Arelaki, S.; Arampatzioglou, A.; Kambas, K.; Ritis, D.; Tsironidou, V.; Moschos, I.; Dalla, V.; et al. REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1β Inflammatory Response in Active Ulcerative Colitis. J. Immunol. 2018, 200, 3950–3961. [Google Scholar] [CrossRef] [PubMed]
  13. Abd El Hafez, A.; Mohamed, A.S.; Shehta, A.; Sheta, H. Neutrophil extracellular traps-associated protein peptidyl arginine deaminase 4 immunohistochemical expression in ulcerative colitis and its association with the prognostic predictors. Pathol. Res. Pract. 2020, 216, 153102. [Google Scholar] [CrossRef]
  14. Wechsler, J.B.; Szabo, A.; Hsu, C.L.; Krier-Burris, R.A.; Schroeder, H.A.; Wang, M.Y.; Carter, R.G.; Velez, T.E.; Aguiniga, L.M.; Brown, J.B.; et al. Histamine drives severity of innate inflammation via histamine 4 receptor in murine experimental colitis. Mucosal Immunol. 2018, 11, 861–870. [Google Scholar] [CrossRef] [PubMed]
  15. Zhang, Y.; Wang, Z.Q.; Liu, J.; Zhang, S.H.; Fei, J.X.; Li, J.; Zhang, T.; Wang, J.D.; Park, P.W.; Chen, Y. Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis. J. Cell Mol. Med. 2017, 21, 13–25. [Google Scholar] [CrossRef] [PubMed]
  16. Cui, C.; Chakraborty, K.; Tang, X.A.; Zhou, G.; Schoenfelt, K.Q.; Becker, K.M.; Hoffman, A.; Chang, Y.F.; Blank, A.; Reardon, C.A.; et al. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell 2021, 184, 3163–3177. [Google Scholar] [CrossRef] [PubMed]
  17. Muthas, D.; Reznichenko, A.; Balendran, C.A.; Bottcher, G.; Clausen, I.G.; Karrman Mardh, C.; Ottosson, T.; Uddin, M.; MacDonald, T.T.; Danese, S.; et al. Neutrophils in ulcerative colitis: A review of selected biomarkers and their potential therapeutic implications. Scand. J. Gastroenterol. 2017, 52, 125–135. [Google Scholar] [CrossRef] [PubMed]
  18. Dong, W.F.; Liu, D.; Zhang, T.T.; You, Q.; Huang, F.J.; Wu, J. Oral delivery of staphylococcal nuclease ameliorates DSS induced ulcerative colitis in mice via degrading intestinal neutrophil extracellular traps. Ecotoxicol. Environ. Safe 2021, 215, 112161. [Google Scholar] [CrossRef] [PubMed]
  19. Brinkmann, V.; Reichard, U.; Goosamnn, C.; Fauler, B.; Uhlemann, Y.; Weiss, D.; Weinrauch, Y.; Zychlinsky, A. Neutrophil extracellular traps kill bacteria. Science 2004, 303, 1532–1535. [Google Scholar] [CrossRef]
  20. Ramos, A.D.; Viana, G.C.S.; Brigido, M.M.; Almeida, J.F. Neutrophil extracellular traps in inflammatory bowel diseases: Implications in pathogenesis and therapeutic targets. Pharmacol. Res. 2021, 171, 105779. [Google Scholar] [CrossRef]
  21. Niu, S.J.; Zhang, X.Y.; Ding, X.K.; Shi, H.Y.; Guo, X.J. The Review of Etiology and Pathogenesis of Ulcerative Colitis. Henan Tradit. Chin. Med. 2019, 39, 799–801. [Google Scholar] [CrossRef]
  22. Liu, X.Y.; He, S.W.; Li, Q.Y.; Mu, X.; Hu, G.; Dong, H. Comparison of the gut microbiota between pulsatilla decoction and levofloxacin hydrochloride therapy on Escherichia coli infection. Front. Cell. Infect. Microbiol. 2020, 10, 319. [Google Scholar] [CrossRef] [PubMed]
  23. Li, Y.H.; Zou, M.; Han, Q.; Deng, L.R.; Weinshilboum, R.M. Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis. Pharmacol. Res. 2020, 160, 105079. [Google Scholar] [CrossRef] [PubMed]
  24. Zhang, W.; Chen, Y.; Jiang, H.; Yang, J.; Wang, Q.; Du, Y.; Xu, H. Integrated strategy for accurately screening biomarkers based on metabolomics coupled with network pharmacology. Talanta 2020, 211, 120710. [Google Scholar] [CrossRef]
  25. Wang, Y.D.; Xu, Z.Q.; Xia, D.; Zhang, M.X.; Wang, T.M.; Shao, J.; Wang, C.Z. Mechanism of butyl alcohol extract of Baitouweng Decoction on ulcerative colitis in mice colonized by Candida albicans based on NLRP3 inflammasome. Chin. Tradit. Herb. Drugs 2022, 53, 3997–4006. [Google Scholar]
  26. Jiang, X.J.; Wang, Y.D.; Sun, J.; Ma, K.L.; Wu, D.Q.; Shao, J.; Wang, T.M.; Wang, C.Z. Mechanism of n-butanol extract of Pulsatilla Decoction in treating ulcerative colitis by activating BMP signaling pathway. China J. Chin. Mater. Medica 2024, 49, 1762–1773. [Google Scholar] [CrossRef]
  27. Kim, J.J.; Shajib, M.S.; Manocha, M.M.; Khan, W.I. Investigating Intestinal Inflammation in DSS-induced Model of IBD. Jove-J. Vis. Exp. 2012, 60, e3678. [Google Scholar] [CrossRef]
  28. Spinelli, A.; Bonovas, S.; Burisch, J.; Kucharzik, T.; Adamina, M.; Annese, V.; Bachmann, O.; Bettenworth, D.; Chaparro, M.; Czuber-Dochan, W.; et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J. Crohns Colitis 2021, 16, 179–189. [Google Scholar] [CrossRef] [PubMed]
  29. Minagawa, Y.; Uchiyama, K.; Takagi, T.; Mizushima, K.; Asaeda, K.; Mariko Kajiwara-Kubota, M.; Kashiwagi, S.; Hotta, Y.; Tanaka, M.; Inoue, K.; et al. Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis. J. Clin. Biochem. Nutr. 2022, 71, 249–254. [Google Scholar] [CrossRef]
  30. Hiraoka, S.; Fujiwara, A.; Toyokawa, T.; Higashi, R.; Moritou, Y.; Takagi, S.; Matsueda, K.; Suzuki, S.; Miyaike, J.; Inokuchi, T.; et al. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 2021, 36, 137–143. [Google Scholar] [CrossRef]
  31. Xie, C.; Quan, R.; Hong, F.; Zou, K.F.; Yan, W.; Fu, Y. The culprit of mesalamine intolerance: Case series and literature review. BMC Gastroenterol. 2019, 19, 138. [Google Scholar] [CrossRef]
  32. Kucharzik, T. Living Guideline Colitis ulcerosa. Chirurg 2022, 93, 261–265. [Google Scholar] [CrossRef] [PubMed]
  33. Calafat, M.; Mañosa, M.; Cañete, F.; Domènech, E. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs Aging 2021, 38, 193–203. [Google Scholar] [CrossRef]
  34. Farkas, K.; Molnár, T. A Review on Biosimilar Infliximab, CT-P13, in the Treatment of Inflammatory Bowel Disease. Immunotherapy 2017, 10, 107–117. [Google Scholar] [CrossRef]
  35. Niu, C.; Hu, X.L.; Yuan, Z.W.; Xiao, Y.; Ji, P.; Wei, Y.M.; Hua, Y.L. Pulsatilla decoction improves DSS-induced colitis via modulation of fecal-bacteria-related short-chain fatty acids and intestinal barrier integrity. J. Ethnopharmacol. 2023, 300, 115741. [Google Scholar] [CrossRef] [PubMed]
  36. Shi, R.; Li, J.X.; Shen, H.; Tang, X.D. Experts consensus on traditional Chinese medicine diagnosis and treatment of ulcerative colitis(2023). Chin. J. Tradit. Chin. Med. Pharm. 2024, 39, 288–296. [Google Scholar]
  37. Ungaro, R.; Mehandru, S.; Allen, P.B.; Peyrin-Biroulet, L.; Colombel, J.F. Ulcerative colitis. Lancet 2017, 389, 1756–1770. [Google Scholar] [CrossRef]
  38. Choteau, L.; Vancraeyneste, H.; le Roy, D.; Dubuquoy, L.; Romani, L.; Jouault, T.; Poulain, D.; Sendid, B.; Calandra, T.; Roger, T.; et al. Role of TLR1, TLR2 and TLR6 in the modulation of intestinal inflammation and Candida albicans elimination. Gut Pathog. 2017, 9, 9. [Google Scholar] [CrossRef] [PubMed]
  39. Ma, K.L.; Han, Z.J.; Pan, M.; Chen, M.L.; Ge, Y.Z.; Shao, J.; Wu, D.Q.; Wang, T.M.; Yan, G.M.; Wang, C.Z. Therapeutic effect of cinnamaldehyde on ulcerative colitis in mice induced bydextran sulfate sodium with Candida albicans colonization and its effect ondectin-1/TLRs/NF-κB signaling pathway. China J. Chin. Mater. Medica 2020, 45, 3211–3219. [Google Scholar] [CrossRef]
  40. Castanheira, F.V.S.; Kubes, P. Neutrophils and NETS in modulating acute and chronic inflammation. Blood 2019, 133, 2178–2185. [Google Scholar] [CrossRef]
  41. Hu, K.F.; Zhang, H.; Shi, G.X.; Wang, B.F.; Wu, D.Q.; Shao, J.; Wang, T.M.; Wang, C.Z. Effects of n-butanol extract of Pulsatilla decoction on the NLRP3 inflammasome in macrophages infectedwith Candida albicans. J. Ethnopharmacol. 2023, 304, 116041. [Google Scholar] [CrossRef] [PubMed]
  42. Lee, H.R.; Jeong, Y.J.; Lee, J.W.; Jhun, J.Y.; Na, H.S.; Cho, K.H.; Kim, S.J.; Cho, M.L.; Heo, T.H. Tannic acid, an IL-1β-direct binding compound, ameliorates IL-1β-induced inflammation and cartilage degradation by hindering IL-1β-IL-1R1 interaction. PLoS ONE 2023, 18, e0281834. [Google Scholar] [CrossRef] [PubMed]
  43. Wang, S.K.; Yao, Z.X.; Chen, L.; Li, J.H.; Chen, S.; Fan, C.Y. Preclinical assessment of IL-1β primed human umbilical cord mesenchymal stem cells for tendon functional repair through TGF-β/IL-10 signaling. Heliyon 2023, 9, e21411. [Google Scholar] [CrossRef] [PubMed]
  44. Chen, C.; Tang, Y.Y.; Zhu, X.D.; Yang, J.C.; Liu, Z.H.; Chen, Y.X.; Wang, J.; Shang, R.Y.; Zheng, W.X.; Zhang, X.R.; et al. P311 Promotes IL-4 Receptor-Mediated M2 Polarization of Macrophages to Enhance Angiogenesis for Efficient Skin Wound Healing. J. Investig. Dermatol. 2023, 143, 648–660. [Google Scholar] [CrossRef] [PubMed]
  45. Wang, X.M.; Tian, G.; Duan, Q.J.; Wu, D.Q.; Shao, J.; Wang, T.M.; Wang, C.Z. Therapeutic potential of n-butanol extract of Pulsatilla decoction in a murine model of ulcerative colitis induced by DSS combined with Candida albicans colonization. China J. Chin. Mater. Medica 2018, 43, 2979–2984. [Google Scholar] [CrossRef]
  46. Guo, W.J.; Liu, W.; Jin, B.; Geng, J.; Li, J.; Ding, H.Q.; Wu, X.F.; Xu, Q.; Sun, Y.; Gao, J. Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation. Int. Immunopharmacol. 2015, 24, 232–238. [Google Scholar] [CrossRef] [PubMed]
  47. Du, L.D.; Ma, Q.L.; Wu, G.T.; Shao, J.; Cao, R.B.; Zang, K.H.; Ren, Y. Mechanism Study of Wumeiwan in the Treatment of Ulcerative Colitis ViaIKKα/NF-κB/COX-2 Signaling Pathways in the Colon tissue of Rats. Pharmacol. Clin. Chin. Mater. Medica 2021, 37, 3–7. [Google Scholar] [CrossRef]
  48. Yu, Z.Y.; Xu, Y.S.; Tang, M.; Xin, W.F. The effect of olsalazine of chinese generic drugs on ulcerative colitis induced by dextran sulfate sodium salt in BALB/c mice. Acta Cir. Bras. 2023, 38, e382923. [Google Scholar] [CrossRef]
Pharmaceuticals 17 01077 g001
Figure 1. HPLC fingerprint of major components of BEPD. HPLC fingerprint of (A) anemoside B4, (B) phellodendrine, (C) esculin and esculetin, (D) epiberberine and berberine, and (E) jatrorrhizine of BEPD.
Figure 1. HPLC fingerprint of major components of BEPD. HPLC fingerprint of (A) anemoside B4, (B) phellodendrine, (C) esculin and esculetin, (D) epiberberine and berberine, and (E) jatrorrhizine of BEPD.
Pharmaceuticals 17 01077 g001
Pharmaceuticals 17 01077 g002
Figure 2. (A) Body weight changes. (B) Effect of BEPD on DAI score in UC mice induced by DSS.
Figure 2. (A) Body weight changes. (B) Effect of BEPD on DAI score in UC mice induced by DSS.
Pharmaceuticals 17 01077 g002
Pharmaceuticals 17 01077 g003
Figure 3. Anti-UC effects of BEPD against DSS-induced UC mice. (A,B) Representative pictures of colons from each group and the length of the mouse colon. (C) Representative HE staining of distal colon tissues (200× magnification). (D) Pathological score of mouse colon tissue. (E) Score of CMDI. (F) In the colon mucosal permeability experiment. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Figure 3. Anti-UC effects of BEPD against DSS-induced UC mice. (A,B) Representative pictures of colons from each group and the length of the mouse colon. (C) Representative HE staining of distal colon tissues (200× magnification). (D) Pathological score of mouse colon tissue. (E) Score of CMDI. (F) In the colon mucosal permeability experiment. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Pharmaceuticals 17 01077 g003
Pharmaceuticals 17 01077 g004
Figure 4. Effects of BEPD on cytokine production. (A–C) The levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in serum of UC mice. (D,E) The levels of anti-inflammatory cytokines IL-4 and IL-10 in serum of UC mice. (F–H) The levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in colon tissues of UC mice. (I,J) The levels of anti-inflammatory cytokines IL-4 and IL-10 in colon tissues of UC mice. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Figure 4. Effects of BEPD on cytokine production. (A–C) The levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in serum of UC mice. (D,E) The levels of anti-inflammatory cytokines IL-4 and IL-10 in serum of UC mice. (F–H) The levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in colon tissues of UC mice. (I,J) The levels of anti-inflammatory cytokines IL-4 and IL-10 in colon tissues of UC mice. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Pharmaceuticals 17 01077 g004
Pharmaceuticals 17 01077 g005
Figure 5. Effects of BEPD on chemokine production and PMN infiltration and activation. (A) The levels of neutrophil chemokines CXCL1 and CXCL2 in serum and colon tissues of UC mice. (B,C) Effects of BEPD on PMN infiltration in the colon mucosal tissues (400× magnification). (D) IHC staining of colon ROS of mice in each group (400× magnification). (E) Semi-quantitative results of IHC staining analysis for ROS. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Figure 5. Effects of BEPD on chemokine production and PMN infiltration and activation. (A) The levels of neutrophil chemokines CXCL1 and CXCL2 in serum and colon tissues of UC mice. (B,C) Effects of BEPD on PMN infiltration in the colon mucosal tissues (400× magnification). (D) IHC staining of colon ROS of mice in each group (400× magnification). (E) Semi-quantitative results of IHC staining analysis for ROS. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Pharmaceuticals 17 01077 g005
Pharmaceuticals 17 01077 g006
Figure 6. Effects of BEPD on the formation of NETs. (A–E) Western blot results of key proteins involved in NET formation, Cit H3, MPO, PAD4, and ELANE. (## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Figure 6. Effects of BEPD on the formation of NETs. (A–E) Western blot results of key proteins involved in NET formation, Cit H3, MPO, PAD4, and ELANE. (## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Pharmaceuticals 17 01077 g006
Pharmaceuticals 17 01077 g007
Figure 7. Effects of BEPD on the release of NETs. (A–E) IHC staining and semi-quantitative results of colon MPO, MMP-8, MMP-9, PAD4, and ELANE of mice in each group (400× magnification). (F) Relative content of MPO, MMP-8, MMP-9, and ELANE in mouse feces. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Figure 7. Effects of BEPD on the release of NETs. (A–E) IHC staining and semi-quantitative results of colon MPO, MMP-8, MMP-9, PAD4, and ELANE of mice in each group (400× magnification). (F) Relative content of MPO, MMP-8, MMP-9, and ELANE in mouse feces. (# p < 0.05 vs. control group, ## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Pharmaceuticals 17 01077 g007
Pharmaceuticals 17 01077 g008aPharmaceuticals 17 01077 g008b
Figure 8. Effect of BEPD on extracellular NET. (A,B) MPO and Cit H3 co-located with DNA. (C,D) ELANE and MPO co-located with DNA. (## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Figure 8. Effect of BEPD on extracellular NET. (A,B) MPO and Cit H3 co-located with DNA. (C,D) ELANE and MPO co-located with DNA. (## p < 0.01 vs. control group, * p < 0.05 vs. model group, ** p < 0.01 vs. model group. * p < 0.05 indicates statistically significant).
Pharmaceuticals 17 01077 g008aPharmaceuticals 17 01077 g008b
Table 1. The retention time, peak areas, and contents of esculin, esculetin, epiberberine, berberine, phellodendrine, jatrorrhizine, and anemoside B4 in BEPD.
Table 1. The retention time, peak areas, and contents of esculin, esculetin, epiberberine, berberine, phellodendrine, jatrorrhizine, and anemoside B4 in BEPD.
Main ComponentsRetention Time
(min)		Peak Area
(mAU × min)		Content
(μg/g)
Anemoside B412.71117.50678,116.529
Phellodendrine12.5302.8283294.236
Berberine18.91399.16765,110.351
Epiberberine11.83313.9234177.739
Esculin6.238124.41859,261.456
Esculetin11.2231.531514.884
Jatrorrhizine17.32847.88314,949.716
Table 2. Scoring criteria of DAI.
Table 2. Scoring criteria of DAI.
ScoreWeight Loss (%)Stool ConditionFecal Blood
0n ≤ 1%formed, moderate hardnessno abnormalities
11% < n ≤ 5%formed, soft, not adhering to the perianal areafeces with dark red spots
25% < n ≤ 10%soft and sticky around the anusfeces with dark red spots and visible bleeding around the anus
3n > 10%unformed, adhering to the perianal area, diarrheadeep red feces with adhesion of perianal blood
Table 3. Scoring criteria of colonic histopathology.
Table 3. Scoring criteria of colonic histopathology.
ScoreSeverity of InflammationRange of InflammationAmount of Crypt Damage
0nonenonenone
1mildmucosa1/3 damaged
2moderatemucosa and submucosa2/3 damaged, and epithelial surface present
3severetransmuralcrypts and epithelial surface lost
Table 4. Scoring criteria of CMDI.
Table 4. Scoring criteria of CMDI.
ScoreMucosal Injury Degree
0normal intestinal mucosa
1mucosa congestion without ulcer lesions and bleeding
2sporadic mucosal ulcer or slight bleeding
3extensive ulcer necrosis or adhesion of intestinal mucosa and bleeding
4severe bleeding and megacolon or stenosis or perforation
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, Y.; Wu, H.; Sun, J.; Li, C.; Fang, Y.; Shi, G.; Ma, K.; Wu, D.; Shao, J.; Song, H.; et al. Effects of the N-Butanol Extract of Pulsatilla Decoction on Neutrophils in a Mouse Model of Ulcerative Colitis. Pharmaceuticals 2024, 17, 1077. https://doi.org/10.3390/ph17081077

AMA Style

Wang Y, Wu H, Sun J, Li C, Fang Y, Shi G, Ma K, Wu D, Shao J, Song H, et al. Effects of the N-Butanol Extract of Pulsatilla Decoction on Neutrophils in a Mouse Model of Ulcerative Colitis. Pharmaceuticals. 2024; 17(8):1077. https://doi.org/10.3390/ph17081077

Chicago/Turabian Style

Wang, Yadong, Hui Wu, Juan Sun, Can Li, Ying Fang, Gaoxiang Shi, Kelong Ma, Daqiang Wu, Jing Shao, Hang Song, and et al. 2024. "Effects of the N-Butanol Extract of Pulsatilla Decoction on Neutrophils in a Mouse Model of Ulcerative Colitis" Pharmaceuticals 17, no. 8: 1077. https://doi.org/10.3390/ph17081077

APA Style

Wang, Y., Wu, H., Sun, J., Li, C., Fang, Y., Shi, G., Ma, K., Wu, D., Shao, J., Song, H., Wang, T., & Wang, C. (2024). Effects of the N-Butanol Extract of Pulsatilla Decoction on Neutrophils in a Mouse Model of Ulcerative Colitis. Pharmaceuticals, 17(8), 1077. https://doi.org/10.3390/ph17081077

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop